These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29949805)

  • 41. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
    Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications.
    Manso J; Bertazza L; Barollo S; Mondin A; Censi S; Carducci S; Ferrara AM; Boschin IM; Zovato S; Schiavi F; Gregianin M; Pennelli G; Iacobone M; Mian C
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
    Kornaczewski ER; Pointon OP; Burgess JR
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET.
    Timmers HJ; Carrasquillo JA; Whatley M; Eisenhofer G; Chen CC; Ling A; Linehan WM; Pinto PA; Adams KT; Pacak K
    J Nucl Med; 2007 Dec; 48(12):1940-4. PubMed ID: 18006611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dysfunction of calcium-regulated exocytosis at a single-cell level causes catecholamine hypersecretion in patients with pheochromocytoma.
    Houy S; Streit L; Drissa I; Rame M; Decraene C; Moog S; Brunaud L; Lanoix J; Chelbi R; Bihain F; Lacomme S; Lomazzi S; Campoli P; Vix M; Mutter D; Paramithiotis E; Dubessy C; Vitale N; Ory S; Gasman S
    Cancer Lett; 2022 Sep; 543():215765. PubMed ID: 35680072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor.
    Eisenhofer G; Goldstein DS; Kopin IJ; Crout JR
    Endocr Pathol; 2003; 14(3):193-212. PubMed ID: 14586065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
    Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
    J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?
    Grouzmann E; Tschopp O; Triponez F; Matter M; Bilz S; Brändle M; Drechser T; Sigrist S; Zulewski H; Henzen C; Fischli S; Abid K
    PLoS One; 2015; 10(5):e0125426. PubMed ID: 25946206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma: a single center experience over 11 years.
    Yamamoto S; Hellman P; Wassberg C; Sundin A
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2423-32. PubMed ID: 22563107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1.
    Képénékian L; Mognetti T; Lifante JC; Giraudet AL; Houzard C; Pinson S; Borson-Chazot F; Combemale P
    Eur J Endocrinol; 2016 Oct; 175(4):335-44. PubMed ID: 27450695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by
    Rotania M; Chabrier G; Imperiale A
    Endocrine; 2019 Dec; 66(3):691-692. PubMed ID: 31478160
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical utility of chromogranin A in SDHx-related paragangliomas.
    Zuber S; Wesley R; Prodanov T; Eisenhofer G; Pacak K; Kantorovich V
    Eur J Clin Invest; 2014 Apr; 44(4):365-71. PubMed ID: 24467715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catecholamine metabolism in pheochromocytoma and normal adrenal medullae.
    Nakada T; Furuta H; Katayama T
    J Urol; 1988 Dec; 140(6):1348-51. PubMed ID: 2903937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
    Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
    Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma free metanephrine, normetanephrine, and 3-methoxytyramine for the diagnosis of pheochromocytoma/paraganglioma.
    Gupta P; Khurana ML; Khadgawat R; Bal CS; Kumar G; Sharma SC; Tandon N
    Indian J Endocrinol Metab; 2015; 19(5):633-8. PubMed ID: 26425473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biochemical and radiological relationships in patients with pheochromocytoma: lessons from a case control study.
    Kannan S; Purysko A; Faiman C; Remer EM; Shah L; Bena J; Siperstein A; Berber E; Fergany A; Bravo E; Hamrahian AH
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):790-6. PubMed ID: 24494743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple endocrine neoplasia 2A (MEN 2A) syndrome.
    Breza J; Breza J
    Bratisl Lek Listy; 2018; 119(2):120-125. PubMed ID: 29455549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.